Multiple Myeloma Specialty Channel

Multiple Myeloma

Specialty Channel

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

News

Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM

03/05/2024

Jordan Kadish

According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...

According to a phase 3 trial,...

03/05/2024

Oncology

FDA Approval

FDA Approves Biweekly Dosing of Teclistamab for Patients With Relapsed/Refractory Multiple Myeloma

02/21/2024

Jordan Kadish

On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.

On February 20, 2024, the FDA...

02/21/2024

Oncology

News

Addition of Elotuzumab to Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation and Lenalidomide Maintenance Fail to Provide Survival Benefit Among Patients With Newly Diagnosed MM

02/16/2024

Amber Denham

The addition of elotuzumab to lenalidomide, bortezomib, and dexamethasone induction or consolidation and lenalidomide maintenance fails to provide clinical benefit for patients with transplant-eligible newly diagnosed multiple myeloma who are...

The addition of elotuzumab to...

02/16/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

News

Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM

03/05/2024

Jordan Kadish

According to a phase 3 trial,...

03/05/2024

Oncology

FDA Approval

FDA Approves Biweekly Dosing of Teclistamab for Patients With Relapsed/Refractory Multiple Myeloma

02/21/2024

Jordan Kadish

On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.

On February 20, 2024, the FDA...

02/21/2024

Oncology

News

Addition of Elotuzumab to Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation and Lenalidomide Maintenance Fail to Provide Survival Benefit Among Patients With Newly Diagnosed MM

02/16/2024

Amber Denham

The addition of elotuzumab to...

02/16/2024

Oncology

Interactive Features

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

Quiz

Treating R/R Multiple Myeloma With Fractionated BCMA-Directed CAR T-Cell Therapy ARI0002h

01/30/2024

According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...

According to an interim analysis...

01/30/2024

Oncology

Quiz

Mezigdomide Plus Dexamethasone Oral Combination for Patients With Heavily Pretreated R/R MM

01/19/2024

True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.

True or False: The oral...

01/19/2024

Oncology

Quiz

Quiz: Ciltacabtagene Autoleucel CAR T-Cell Therapy for Patients With R/R Multiple Myeloma With Prior BCMA-Targeting Therapy

04/18/2023

In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...

In a study assessing the...

04/18/2023

Oncology

Quiz

Quiz: Triplet Therapy With Lenalidomide, Bortezomib, and Dexamethasone Alone or With Autologous SCT for MM

09/13/2022

True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...

True or False: Among adults with...

09/13/2022

Oncology

Quiz

Quiz: Responses to MRD-Adapted Study Design Employing Quadruplet Therapy Without Transplant in Patients With MM

09/02/2022

True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...

True or false: In a phase 2...

09/02/2022

Oncology

Quiz

Quiz: Treatment With Teclistamab for Patients With Triple-Class Exposed Relapsed/Refractory MM

08/24/2022

Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?

Quiz: Among patients with...

08/24/2022

Oncology

Test Your Knowledge

Quiz: Is TNB-383B Well Tolerated in R/R MM?

02/01/2022

True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.

True or false: TNB-383B, a BCMA...

02/01/2022

Oncology

Test Your Knowledge

Quiz: Do Gamma Secretase Inhibitors Increase BCMA Expression?

02/01/2022

True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.

True or false: Gamma secretase...

02/01/2022

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Target Both BCMA and CD3 Receptors for MM?

01/27/2022

True or false: Teclistamab targets both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressive myeloma cells.

True or false: Teclistamab...

01/27/2022

Oncology

Recent News

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

News

Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM

03/05/2024

Jordan Kadish

According to a phase 3 trial,...

03/05/2024

Oncology

FDA Approval

FDA Approves Biweekly Dosing of Teclistamab for Patients With Relapsed/Refractory Multiple Myeloma

02/21/2024

Jordan Kadish

On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.

On February 20, 2024, the FDA...

02/21/2024

Oncology

News

Addition of Elotuzumab to Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation and Lenalidomide Maintenance Fail to Provide Survival Benefit Among Patients With Newly Diagnosed MM

02/16/2024

Amber Denham

The addition of elotuzumab to...

02/16/2024

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology